333 related articles for article (PubMed ID: 28430376)
21. Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma.
Korman AM; Tyler KH; Kaffenberger BH
Int J Dermatol; 2017 Apr; 56(4):e75-e77. PubMed ID: 28102540
[No Abstract] [Full Text] [Related]
22. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
Adler NR; Murray WK; Brady B; McCormack C; Pan Y
Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853
[No Abstract] [Full Text] [Related]
23. Diet-dependent toxicity of ipilimumab in metastatic melanoma.
Majenka P; Hoffmann M; Rötzer I; Dimitrakopoulou-Strauss A; Koschny R; Longerich T; Enk A; Hassel JC
Eur J Cancer; 2019 Jan; 106():220-224. PubMed ID: 30528806
[No Abstract] [Full Text] [Related]
24. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
25. Checkpoint Inhibitor-Associated Hypophysitis.
Chang LS; Yialamas MA
J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
[No Abstract] [Full Text] [Related]
26. Nivolumab PD-1 inhibitor immunotherapy associated with vulvar, perineal and perianal lichen sclerosus.
Wernham AGH; Shah F; Velangi S
Clin Exp Dermatol; 2019 Mar; 44(2):e22-e23. PubMed ID: 30430637
[No Abstract] [Full Text] [Related]
27. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
[TBL] [Abstract][Full Text] [Related]
28. Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy.
Apostolova P; Unger S; von Bubnoff D; Meiss F; Becher B; Zeiser R
N Engl J Med; 2020 Jan; 382(3):294-296. PubMed ID: 31940706
[No Abstract] [Full Text] [Related]
29. Ipilimumab prolongs survival in advanced melanoma.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
[No Abstract] [Full Text] [Related]
30. Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma.
Mencel J; Gargett T; Karanth N; Pokorny A; Brown MP; Charakidis M
Asia Pac J Clin Oncol; 2019 Dec; 15(6):383-386. PubMed ID: 31373116
[TBL] [Abstract][Full Text] [Related]
31. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
[TBL] [Abstract][Full Text] [Related]
32. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
Tsiogka A; Jansky GL; Bauer JW; Koelblinger P
Melanoma Res; 2017 Oct; 27(5):524-525. PubMed ID: 28858175
[No Abstract] [Full Text] [Related]
33. Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy.
Mangana J; Buset CS; Dummer R
JAMA Oncol; 2019 May; 5(5):730-731. PubMed ID: 30676614
[No Abstract] [Full Text] [Related]
34. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
Donaldson M; Owen JL; Choi JN
JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
[No Abstract] [Full Text] [Related]
35. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma.
Pach J; Olamiju B; Weiss S; Damsky W; Leventhal J
JAMA Dermatol; 2021 Apr; 157(4):468-469. PubMed ID: 33688919
[No Abstract] [Full Text] [Related]
36. Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma.
Latchman J; Guastella A; Tofthagen C
Clin J Oncol Nurs; 2019 Aug; 23(4):355-358. PubMed ID: 31322610
[TBL] [Abstract][Full Text] [Related]
37. Isolated Adrenocorticotropic Hormone Deficiency in Melanoma Patients Treated with Nivolumab.
Kitano S; Tatsuno K; Ishibe J; Shimauchi T; Fujiyama T; Ito T; Ogawa N; Tokura Y
Acta Derm Venereol; 2018 Jul; 98(7):704-705. PubMed ID: 29405244
[No Abstract] [Full Text] [Related]
38. Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression.
Meti N; Petrogiannis-Haliotis T; Esfahani K
J Oncol Pract; 2018 Aug; 14(8):514-516. PubMed ID: 30004823
[No Abstract] [Full Text] [Related]
39. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.
Wada N; Uchi H; Furue M
J Dermatol; 2017 Aug; 44(8):e196-e197. PubMed ID: 28391613
[No Abstract] [Full Text] [Related]
40. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
